Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells

Neurobiology of Disease

Volumn 34, Issue 3, 2009, Pages 487-500

  Van Laar, Victor S ^a   Mishizen, Amanda J ^a   Cascio, Michael ^a   Hastings, Teresa G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

DJ 1; Dopamine oxidation; Mitochondrial creatine kinase; Mitochondrion; Mitofilin; Parkinson's disease; Protein modification; Proteomics; SH SY5Y; UCH L1

Indexed keywords

BRAIN PROTEIN; CHAPERONIN; CREATINE KINASE; DOPAMINE; DOPAMINE C 14; DOPAMINE CONJUGATED PROTEIN; GLUCOSE REGULATED PROTEIN 75; HEAT SHOCK PROTEIN 70; MITOFILIN; QUINONE DERIVATIVE; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUITIN CARBOXY TERMINAL HYDROLASE DJ1; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; COVALENT BOND; MALE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEOMICS; RAT;

ANIMALS; BENZOQUINONES; BRAIN; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHAPERONINS; CREATINE KINASE, MITOCHONDRIAL FORM; DOPAMINE; ELECTRON TRANSPORT COMPLEX III; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; OXIDANTS; OXIDATION-REDUCTION; RATS; UBIQUITIN THIOLESTERASE;

EID: 67349280174     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.03.004     Document Type: Article

References (102)

1. Ahmed N., and Rice G.E. Strategies for revealing lower abundance proteins in two-dimensional protein maps. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815 (2005) 39-50
2. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., and Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103 (2001) 373-383
3. Bandopadhyay R., Kingsbury A.E., Cookson M.R., Reid A.R., Evans I.M., Hope A.D., Pittman A.M., Lashley T., Canet-Aviles R., Miller D.W., McLendon C., Strand C., Leonard A.J., Abou-Sleiman P.M., Healy D.G., Ariga H., Wood N.W., de Silva R., Revesz T., Hardy J.A., and Lees A.J. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127 (2004) 420-430
4. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4 (2004) 3943-3952
5. Beal M.F. Mitochondria and neurodegeneration. Novartis Found Symp. 287 (2007) 183-192 discussion 192-6
6. Ben-Shachar D., Zuk R., Gazawi H., and Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 67 (2004) 1965-1974
7. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
8. Berman S.B., Watkins S.C., and Hastings T.G. Quantitative biochemical and ultrastructural comparison of mitochondrial permeability transition in isolated brain and liver mitochondria: evidence for reduced sensitivity of brain mitochondria. Exp. Neurol. 164 (2000) 415-425
9. Berman S.B., Zigmond M.J., and Hastings T.G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67 (1996) 593-600
10. Bienvenut W.V., Sanchez J.C., Karmime A., Rouge V., Rose K., Binz P.A., and Hochstrasser D.F. Toward a clinical molecular scanner for proteome research: parallel protein chemical processing before and during western blot. Anal. Chem. 71 (1999) 4800-4807
11. Blandini F., Nappi G., and Greenamyre J.T. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Mov. Disord. 13 (1998) 11-15
12. Boldogh I.R., and Pon L.A. Interactions of mitochondria with the actin cytoskeleton. Biochim. Biophys. Acta 1763 (2006) 450-462
13. Boldogh I.R., and Pon L.A. Mitochondria on the move. Trends Cell Biol. 17 (2007) 502-510
14. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
16. Brandina I., Graham J., Lemaitre-Guillier C., Entelis N., Krasheninnikov I., Sweetlove L., Tarassov I., and Martin R.P. Enolase takes part in a macromolecular complex associated to mitochondria in yeast. Biochim. Biophys. Acta 1757 (2006) 1217-1228
17. Brenner-Lavie H., Klein E., Zuk R., Gazawi H., Ljubuncic P., and Ben-Shachar D. Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochim. Biophys. Acta 1777 (2008) 173-185
18. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., and Cookson M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9103-9108
19. Carre M., Andre N., Carles G., Borghi H., Brichese L., Briand C., and Braguer D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 277 (2002) 33664-33669
20. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., and Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33 (2002) 562-571
21. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., and Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85 (2003) 1394-1401
22. Choi J., Forster M.J., McDonald S.R., Weintraub S.T., Carroll C.A., and Gracy R.W. Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. Free Radic. Biol. Med. 36 (2004) 1155-1162
23. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279 (2004) 13256-13264
24. Choi J., Sullards M.C., Olzmann J.A., Rees H.D., Weintraub S.T., Bostwick D.E., Gearing M., Levey A.I., Chin L.S., and Li L. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281 (2006) 10816-10824
25. Cohen G., Farooqui R., and Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4890-4894
26. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
27. Cumming R.C., Andon N.L., Haynes P.A., Park M., Fischer W.H., and Schubert D. Protein disulfide bond formation in the cytoplasm during oxidative stress. J. Biol. Chem. 279 (2004) 21749-21758
28. De Simoni S., Goemaere J., and Knoops B. Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci. Lett. 433 (2008) 219-224
29. Dukes A.A., Van Laar V.S., Cascio M., and Hastings T.G. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J. Neurochem. 106 (2008) 333-346
30. Eder M., Stolz M., Wallimann T., and Schlattner U. A conserved negatively charged cluster in the active site of creatine kinase is critical for enzymatic activity. J. Biol. Chem. 275 (2000) 27094-27099
31. Ellgaard L., and Ruddock L.W. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep. 6 (2005) 28-32
32. Entelis N., Brandina I., Kamenski P., Krasheninnikov I.A., Martin R.P., and Tarassov I. A glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in Saccharomyces cerevisiae. Genes Dev. 20 (2006) 1609-1620
33. Fang J., Nakamura T., Cho D.H., Gu Z., and Lipton S.A. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 18742-18747
34. Giege P., Heazlewood J.L., Roessner-Tunali U., Millar A.H., Fernie A.R., Leaver C.J., and Sweetlove L.J. Enzymes of glycolysis are functionally associated with the mitochondrion in Arabidopsis cells. Plant Cell. 15 (2003) 2140-2151
35. Gluck M., Ehrhart J., Jayatilleke E., and Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J. Neurochem. 82 (2002) 66-74
36. Gluck M.R., and Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J. Neurochem. 91 (2004) 788-795
37. Graham D.G., Tiffany S.M., Bell Jr. W.R., and Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978) 644-653
38. Greenamyre J.T., and Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304 (2004) 1120-1122
39. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001) 685-716
40. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 97 (2006) 1634-1658
41. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64 (1995) 919-924
42. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1956-1961
43. Ito S., Kato T., and Fujita K. Covalent binding of catechols to proteins through the sulphydryl group. Biochem. Pharmacol. 37 (1988) 1707-1710
44. Janetzky B., Hauck S., Youdim M.B., Riederer P., Jellinger K., Pantucek F., Zochling R., Boissl K.W., and Reichmann H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169 (1994) 126-128
45. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 discussion S36-8
46. Jin J., Hulette C., Wang Y., Zhang T., Pan C., Wadhwa R., and Zhang J. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics 5 (2006) 1193-1204
47. John G.B., Shang Y., Li L., Renken C., Mannella C.A., Selker J.M., Rangell L., Bennett M.J., and Zha J. The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol. Biol. Cell. 16 (2005) 1543-1554
48. Jones D.C., Gunasekar P.G., Borowitz J.L., and Isom G.E. Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J. Neurochem. 74 (2000) 2296-2304
49. Khan F.H., Saha M., and Chakrabarti S. Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain Res. 895 (2001) 245-249
50. Khan F.H., Sen T., Maiti A.K., Jana S., Chatterjee U., and Chakrabarti S. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim. Biophys. Acta 1741 (2005) 65-74
51. Koshimura K., Tanaka J., Murakami Y., and Kato Y. Effects of dopamine and L-DOPA on survival of PC12 cells. J. Neurosci. Res. 62 (2000) 112-119
52. Kuhn D.M., Arthur Jr. R.E., Thomas D.M., and Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 73 (1999) 1309-1317
53. Lai C.T., and Yu P.H. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53 (1997) 363-372
54. Lame M.W., Jones A.D., Wilson D.W., and Segall H.J. Protein targets of 1,4-benzoquinone and 1,4-naphthoquinone in human bronchial epithelial cells. Proteomics 3 (2003) 479-495
55. Lame M.W., Jones A.D., Wilson D.W., and Segall H.J. Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells. Proteomics 5 (2005) 4398-4413
56. Landino L.M., Hasan R., McGaw A., Cooley S., Smith A.W., Masselam K., and Kim G. Peroxynitrite oxidation of tubulin sulfhydryls inhibits microtubule polymerization. Arch. Biochem. Biophys. 398 (2002) 213-220
57. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
58. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
59. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
60. Luduena R.F., and Roach M.C. Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol. Ther. 49 (1991) 133-152
61. Lutz T., Westermann B., Neupert W., and Herrmann J.M. The mitochondrial proteins Ssq1 and Jac1 are required for the assembly of iron sulfur clusters in mitochondria. J. Mol. Biol. 307 (2001) 815-825
62. Magi B., Ettorre A., Liberatori S., Bini L., Andreassi M., Frosali S., Neri P., Pallini V., and Di Stefano A. Selectivity of protein carbonylation in the apoptotic response to oxidative stress associated with photodynamic therapy: a cell biochemical and proteomic investigation. Cell. Death Differ. 11 (2004) 842-852
63. Maker H.S., Weiss C., and Brannan T.S. Amine-mediated toxicity. The effects of dopamine, norepinephrine, 5-hydroxytryptamine, 6-hydroxydopamine, ascorbate, glutathione and peroxide on the in vitro activities of creatine and adenylate kinases in the brain of the rat. Neuropharmacology 25 (1986) 25-32
64. Miura T., Muraoka S., and Fujimoto Y. Inactivation of creatine kinase induced by dopa and dopamine in the presence of ferrylmyoglobin. Chem. Biol. Interact. 123 (1999) 51-61
65. Montine T.J., Farris D.B., and Graham D.G. Covalent crosslinking of neurofilament proteins by oxidized catechols as a potential mechanism of Lewy body formation. J. Neuropathol. Exp. Neurol. 54 (1995) 311-319
66. Neely M.D., Boutte A., Milatovic D., and Montine T.J. Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res. 1037 (2005) 90-98
67. Neely M.D., Sidell K.R., Graham D.G., and Montine T.J. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J. Neurochem. 72 (1999) 2323-2333
68. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., Hirokawa T., Manago Y., Amano T., Noda M., Aoki S., and Wada K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304 (2003) 176-183
69. Offen D., Ziv I., Sternin H., Melamed E., and Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141 (1996) 32-39
70. Ogawa N., Asanuma M., Miyazaki I., Diaz-Corrales F.J., and Miyoshi K. L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J. Neurol. 252 Suppl. 4 (2005) IV23-IV31
71. Okudo H., Urade R., Moriyama T., and Kito M. Catalytic cysteine residues of ER-60 protease. FEBS Lett. 465 (2000) 145-147
72. Orth M., and Schapira A.H. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40 (2002) 533-541
73. Osorio C., Sullivan P.M., He D.N., Mace B.E., Ervin J.F., Strittmatter W.J., and Alzate O. Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. Neurobiol. Aging 28 (2007) 1853-1862
74. Otsu M., Urade R., Kito M., Omura F., and Kikuchi M. A possible role of ER-60 protease in the degradation of misfolded proteins in the endoplasmic reticulum. J. Biol. Chem. 270 (1995) 14958-14961
75. Premkumar A., and Simantov R. Mitochondrial voltage-dependent anion channel is involved in dopamine-induced apoptosis. J. Neurochem. 82 (2002) 345-352
76. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., and Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16 (2000) 135-142
77. Rabinovic A.D., Lewis D.A., and Hastings T.G. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101 (2000) 67-76
78. Reed T., Perluigi M., Sultana R., Pierce W.M., Klein J.B., Turner D.M., Coccia R., Markesbery W.R., and Butterfield D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30 (2008) 107-120
79. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., and Marsden C.D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53 (1989) 692-697
80. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 (2004) 1783-1793
81. Santa-Maria I., Hernandez F., Smith M.A., Perry G., Avila J., and Moreno F.J. Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Mol. Cell Biochem. 278 (2005) 203-212
82. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7 (2008) 97-109
83. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
84. Shan Y., Napoli E., and Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum. Mol. Genet. 16 (2007) 929-941
85. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
86. Shi M., Caudle W.M., and Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis (2008) 10.1016/j.nbd.2008.09.004
87. Shoffner J.M., Watts R.L., Juncos J.L., Torroni A., and Wallace D.C. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30 (1991) 332-339
88. Song E.J., Kim Y.S., Chung J.Y., Kim E., Chae S.K., and Lee K.J. Oxidative modification of nucleoside diphosphate kinase and its identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Biochemistry 39 (2000) 10090-10097
89. Stewart B.J., Doorn J.A., and Petersen D.R. Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization. Chem. Res. Toxicol. 20 (2007) 1111-1119
90. Stokes A.H., Hastings T.G., and Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55 (1999) 659-665
91. Suh S.K., Hood B.L., Kim B.J., Conrads T.P., Veenstra T.D., and Song B.J. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics 4 (2004) 3401-3412
92. Tse D.C., McCreery R.L., and Adams R.N. Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19 (1976) 37-40
93. Turan S.C., Shah P., and Pietruszko R. Inactivation of aldehyde dehydrogenase in intact rat liver mitochondria by dopamine. Alcohol 6 (1989) 455-460
94. Urade R., and Kito M. Inhibition by acidic phospholipids of protein degradation by ER-60 protease, a novel cysteine protease, of endoplasmic reticulum. FEBS Lett. 312 (1992) 83-86
95. Urade R., Nasu M., Moriyama T., Wada K., and Kito M. Protein degradation by the phosphoinositide-specific phospholipase C-alpha family from rat liver endoplasmic reticulum. J. Biol. Chem. 267 (1992) 15152-15159
96. Van Laar V.S., Dukes A.A., Cascio M., and Hastings T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 29 (2008) 477-489
97. Vyssokikh M.Y., and Brdiczka D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta Biochim. Pol. 50 (2003) 389-404
98. Wadhwa R., Takano S., Kaur K., Aida S., Yaguchi T., Kaul Z., Hirano T., Taira K., and Kaul S.C. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem. J. 391 (2005) 185-190
99. Xie J., Marusich M.F., Souda P., Whitelegge J., and Capaldi R.A. The mitochondrial inner membrane protein mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled-coil-helix coiled-coil-helix domain-containing protein 3 and 6 and DnaJC11. FEBS Lett. 581 (2007) 3545-3549
100. Xu Y., Stokes A.H., Roskoski Jr. R., and Vrana K.E. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 54 (1998) 691-697
101. Yaguchi T., Aida S., Kaul S.C., and Wadhwa R. Involvement of mortalin in cellular senescence from the perspective of its mitochondrial import, chaperone, and oxidative stress management functions. Ann. N. Y. Acad. Sci. 1100 (2007) 306-311
102. Yoshida E., Mokuno K., Aoki S., Takahashi A., Riku S., Murayama T., Yanagi T., and Kato K. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J. Neurol. Sci. 124 (1994) 25-31